Biotech News

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Aptevo Therapeutics (APVO)Aptevo TherapeuticsEarnings

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantationRefined priming-dose regimen significantly reduces

Related news

Aptevo Therapeutics

Multispecific Immunotherapy Platforms Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct. Mipletamig Mipletamig is a...

Recent company news

Stock data

Close
0.41 USD
Market cap
6.28M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States